Lincoln Pharmaceuticals
- Market cap
- ₹ 1,034 Cr.
- P/E
- 11.6x
- P/B
- 1.35x
- 52-week range
- 440 – 770
- ROE
- 12%
- ROCE
- 16%
- Dividend yield
- 0.4%
- Debt / equity
- 0.01
- Sector
- Pharmaceuticals & Biotechnology
- Industry
- Pharmaceuticals
- Listed on
- NSE, BSE
About
Lincoln Pharmaceuticals Limited is engaged in the business of manufacturing and trading pharmaceutical products, as well as undertaking contract manufacturing from pharmaceuticals companies across India and the globe. The Company’s product categories include tablets, capsules, liquid injection, cream in tubes, eye/ear drops, dry power injection, SVP injectables, dry-powder suspensions, liquid injection, and pharma products. It offers products for anti-infective, respiratory system, gynecology, cardio and CNS (central nervous system), antibacterial, dermatological infection, anti-diabetic, and anti-malaria. The Company is also engaged in building a portfolio of lifestyle and chronic segments, primarily in women’s healthcare and dermatology. The Company caters to approximately 60 countries in Europe, Latin America, Africa, Asia Pacific, Southeast Asia, and 26 states across India. The Company has two manufacturing facilities located in Mehsana and Khatraj, Gujarat.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Pharmaceuticals: 221 companies →Lincoln Pharmaceuticals against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)11.6 against a typical 34.3: cheaper than most peers (1st = cheapest).27th of 220
- Sales growth+14.9% against a typical +15.6% from a year earlier.102nd of 197
- Profit growth+28.6% against a typical +18.9% from a year earlier.72nd of 160
- Share price, 3 months−3.7% against a typical −0.5%.113th of 200
- Size₹ 1,034.4 Cr. market value against a typical ₹ 507.7 Cr. (1st = largest).88th of 199
Credit ratings
Every rating action on file, newest first, including reaffirmations. Open a row for the agency's reasoning. All credit rating updates
Adequate safety
Rated A by 2 agencies- All agencies agree and none has raised a warning.
| Agency | Current rating | Outlook | As of |
|---|---|---|---|
| ICRA | [ICRA]A | Stable | 28 Sep 2026 |
| CRISIL | Crisil A | Stable | 9 Jan 2026 |
| Rating | Details | |||||
|---|---|---|---|---|---|---|
| 28 Sep 2026 | Reaffirmed | [ICRA]A | — | ICRA | ₹ 93 Cr. | |
| 9 Jan 2026 | Reaffirmed | Crisil A | — | CRISIL | ₹ 99 Cr. |
Research by Minerva Capital Research Solutions
Our research team's work on Lincoln PharmaceuticalsAlso covered in
Board meetings
Results dates and other board meetings. Full calendar
| Details | ||
|---|---|---|
| 29 Oct 2026Upcoming | Financial Results | To consider and approve the financial results for the period ended September 30, 2026 |
| 13 Aug 2026 | Financial Results | To consider and approve the financial results for the period ended Jun 30, 2026 |
| 28 May 2026 | Financial Results/Dividend | To consider and approve the Audited (Standalone & Consolidated) financial results for the Quarter and Year ended March 31, 2026 and recommendation of dividend on equity shares of the Company, if any. |
| 12 Feb 2026 | Financial Results | Intimation of board meeting of the Company to consider and approve the unaudited (Standalone and Consolidated) financial results for the period ended December 31, 2025. |
| 13 Nov 2025 | Financial Results | To consider and approve the financial results for the period ended September 30, 2025 |
| 7 Aug 2025 | Financial Results | Intimation of Board Meeting to consider and approve the unaudited financial results for the period ended Jun 30, 2025. |
| 22 May 2025 | Financial Results/Dividend | To consider and approve the Audited (Standalone & Consolidated) financial results for the Quarter and Year ended March 31, 2025 and recommendation of dividend on equity shares of the Company, if any. |
Financials
Consolidated figures in ₹ crore.
| ₹ Cr. | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 156 | 146 | 142 | 147 | 161 | 147 | 168 | 154 | 163 | 166 | 187 | 177 |
| Expenses | 125 | 117 | 124 | 125 | 133 | 123 | 141 | 130 | 138 | 143 | 162 | 150 |
| Operating Profit | 31 | 30 | 18 | 23 | 28 | 24 | 27 | 24 | 25 | 24 | 25 | 27 |
| OPM % | 20% | 20% | 13% | 15% | 18% | 16% | 16% | 15% | 16% | 14% | 13% | 15% |
| Other Income | 9 | 11 | 7 | 10 | 10 | 9 | −7 | 15 | 7 | 15 | −4 | 24 |
| Interest | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 |
| Profit before tax | 37 | 38 | 22 | 29 | 35 | 29 | 16 | 35 | 29 | 35 | 17 | 48 |
| Tax % | 25% | 26% | 16% | 20% | 24% | 28% | 29% | 22% | 31% | 18% | 30% | 24% |
| Net Profit | 28 | 28 | 19 | 24 | 26 | 21 | 12 | 28 | 20 | 29 | 12 | 36 |
| EPS in Rs | 13.8 | 14 | 9.29 | 11.82 | 13.15 | 10.37 | 5.78 | 13.82 | 9.98 | 14.28 | 5.81 | 18.09 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- 5%
- 5 Years
- 10%
- 3 Years
- 10%
- TTM
- 10%
- 10 Years
- 14%
- 5 Years
- 7%
- 3 Years
- 7%
- TTM
- 12%
- 10 Years
- 11%
- 5 Years
- 14%
- 3 Years
- 10%
- TTM
- —
- 10 Years
- 16%
- 5 Years
- 15%
- 3 Years
- 14%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| Lincoln Pharmaceuticals | ₹ 560.00 | ₹ 1,034 Cr. | 11.6x | 1.4x | 12% | — |
| Sun Pharmaceutical Industries | ₹ 1,743.00 | ₹ 4,18,194 Cr. | 38.4x | 5.6x | 14.2% | 19.1% |
| Divi's Laboratories | ₹ 8,984.00 | ₹ 2,38,497 Cr. | 73.3x | 11.5x | 16.2% | 24.3% |
| Torrent Pharmaceuticals | ₹ 4,482.00 | ₹ 1,70,475 Cr. | 72.7x | 19.2x | 27.1% | 15.3% |
| Cipla | ₹ 1,337.00 | ₹ 1,08,011 Cr. | 27.6x | 3.3x | 11.8% | 13.7% |
| Zydus Lifesciences | ₹ 1,127.85 | ₹ 1,12,503 Cr. | 21.2x | 4.2x | 19.7% | 18.5% |
Management
- Darshit A. Shah
- Chief Financial Officer
- Trusha Kashish Shah
- Compliance Officer, Company Secretary
- Mahendrabhai Gulabdas Patel
- Managing Director, Executive Director
- Ashish Rajanikant Patel
- Whole Time Director
- Hasmukhbhai Ishwarlal Patel
- Whole Time Director
- Munjal Mahendrabhai Patel
- Whole Time Director
Prices are delayed and for information only. Nothing on this page is investment advice.